Treating lung diseases is a high priority--chronic lung diseases are the fourth leading cause of death in the U.S. Now a Canadian team has successfully treated a rare, progressive lung disease, pulmonary hypertension, using the patient's own genetically-modified adult stem cells.

The company Osiris has also started a Phase II clinical trial using its adult stem cell product, Prochymal, for moderate to severe chronic obstructive lung disease.

Researchers at Vermont College of Medicine have also shown that cord blood stem cells has the potential to regenerate lung tissue.